Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 507

1.

Fremanezumab for the preventive treatment of migraine.

Silberstein SD, Cohen JM, Yeung PP.

Expert Opin Biol Ther. 2019 Jun 10. doi: 10.1080/14712598.2019.1627323. [Epub ahead of print]

PMID:
31177856
2.

Pathophysiology, prevention, and treatment of medication overuse headache.

Diener HC, Dodick D, Evers S, Holle D, Jensen RH, Lipton RB, Porreca F, Silberstein S, Schwedt T.

Lancet Neurol. 2019 Jun 4. pii: S1474-4422(19)30146-2. doi: 10.1016/S1474-4422(19)30146-2. [Epub ahead of print] Review.

PMID:
31174999
3.

Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine.

Ashina M, Goadsby PJ, Reuter U, Silberstein S, Dodick D, Rippon GA, Klatt J, Xue F, Chia V, Zhang F, Cheng S, Mikol DD.

Cephalalgia. 2019 May 30:333102419854082. doi: 10.1177/0333102419854082. [Epub ahead of print]

PMID:
31146544
4.

Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: Analysis of PREEMPT data.

Dodick DW, Silberstein SD, Lipton RB, DeGryse RE, Adams AM, Diener HC.

Cephalalgia. 2019 May 21:333102418825382. doi: 10.1177/0333102418825382. [Epub ahead of print]

PMID:
31112399
5.

Vestibular Neuroscience for the Headache Specialist.

Balaban CD, Black RD, Silberstein SD.

Headache. 2019 May 11. doi: 10.1111/head.13550. [Epub ahead of print]

PMID:
31077365
6.

Remote Electrical Neuromodulation (REN) Relieves Acute Migraine: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial.

Yarnitsky D, Dodick DW, Grosberg BM, Burstein R, Ironi A, Harris D, Lin T, Silberstein SD.

Headache. 2019 May 9. doi: 10.1111/head.13551. [Epub ahead of print]

PMID:
31074005
7.

Adherence to the 2008 IHS guidelines for controlled trials of drugs for the preventive treatment of chronic migraine in adults.

Deen M, Martinelli D, Pijpers J, Diener HC, Silberstein S, Ferrari MD, Ashina M, Tassorelli C, Yuan H.

Cephalalgia. 2019 May 1:333102419847751. doi: 10.1177/0333102419847751. [Epub ahead of print]

PMID:
31042062
8.

Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study.

Lipton RB, Tepper SJ, Reuter U, Silberstein S, Stewart WF, Nilsen J, Leonardi DK, Desai P, Cheng S, Mikol DD, Lenz R.

Neurology. 2019 May 7;92(19):e2250-e2260. doi: 10.1212/WNL.0000000000007452. Epub 2019 Apr 17.

PMID:
30996060
9.

Safety and Tolerability of Fremanezumab for the Prevention of Migraine: A Pooled Analysis of Phases 2b and 3 Clinical Trials.

Silberstein SD, McAllister P, Ning X, Faulhaber N, Lang N, Yeung P, Schiemann J, Aycardi E, Cohen JM, Janka L, Yang R.

Headache. 2019 Jun;59(6):880-890. doi: 10.1111/head.13534. Epub 2019 Apr 12.

PMID:
30977520
10.

The endocannabinoid system in migraine: from bench to pharmacy and back.

Tassorelli C, Greco R, Silberstein SD.

Curr Opin Neurol. 2019 Jun;32(3):405-412. doi: 10.1097/WCO.0000000000000688.

PMID:
30883435
11.

Current Status of Antiepileptic Drugs as Preventive Migraine Therapy.

Parikh SK, Silberstein SD.

Curr Treat Options Neurol. 2019 Mar 18;21(4):16. doi: 10.1007/s11940-019-0558-1. Review.

PMID:
30880369
12.

Invited Commentary on Preventive Anti-Migraine Therapy (PAMT).

Jain S, Silberstein SD.

Curr Treat Options Neurol. 2019 Mar 14;21(4):14. doi: 10.1007/s11940-019-0555-4. Review.

PMID:
30868470
13.

Development of a claims-based algorithm to identify potentially undiagnosed chronic migraine patients.

Pavlovic JM, Yu JS, Silberstein SD, Reed ML, Kawahara SH, Cowan RP, Dabbous F, Campbell KL, Shewale AR, Pulicharam R, Kowalski JW, Viswanathan HN, Lipton RB.

Cephalalgia. 2019 Apr;39(4):465-476. doi: 10.1177/0333102418825373. Epub 2019 Mar 9.

PMID:
30854881
14.

Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition.

Diener HC, Tassorelli C, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ, Mandrekar J; International Headache Society Clinical Trials Standing Committee.

Cephalalgia. 2019 May;39(6):687-710. doi: 10.1177/0333102419828967. Epub 2019 Feb 26.

15.

Migraine Headache: Diagnosis and Current and Emerging Preventive Treatments.

Lipton RB, Silberstein S.

Prim Care Companion CNS Disord. 2018 Dec 27;20 suppl E1. pii: li17059su1c. doi: 10.4088/PCC.li17059su1c.

PMID:
30698925
16.

Calcitonin Gene-Related Peptide Antagonists in the Treatment of Episodic Migraine.

Yuan H, White CS, Silberstein SD.

Clin Pharmacol Ther. 2019 May;105(5):1121-1129. doi: 10.1002/cpt.1356. Epub 2019 Mar 18.

PMID:
30648737
17.

Assessing real-time signaling and agonist-induced CRHR1 internalization by optical methods.

Dos Santos Claro PA, Inda C, Armando NG, Piazza VG, Attorresi A, Silberstein S.

Methods Cell Biol. 2019;149:239-257. doi: 10.1016/bs.mcb.2018.08.009. Epub 2018 Sep 17.

PMID:
30616823
18.

The Effect of Beginning Treatment With Fremanezumab on Headache and Associated Symptoms in the Randomized Phase 2 Study of High Frequency Episodic Migraine: Post-Hoc Analyses on the First 3 Weeks of Treatment.

Silberstein SD, Rapoport AM, Loupe PS, Aycardi E, McDonald M, Yang R, Bigal ME.

Headache. 2019 Mar;59(3):383-393. doi: 10.1111/head.13446. Epub 2018 Nov 18.

PMID:
30450545
19.

Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study.

Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB; COL MIG-301 Study Group.

Neurology. 2018 Dec 11;91(24):e2222-e2232. doi: 10.1212/WNL.0000000000006641. Epub 2018 Nov 16.

20.

A fluorescence nanoscopy marker for corticotropin-releasing hormone type 1 receptor: computer design, synthesis, signaling effects, super-resolved fluorescence imaging, and in situ affinity constant in cells.

Szalai AM, Armando NG, Barabas FM, Stefani FD, Giordano L, Bari SE, Cavasotto CN, Silberstein S, Aramendía PF.

Phys Chem Chem Phys. 2018 Nov 28;20(46):29212-29220. doi: 10.1039/c8cp06196c.

PMID:
30427333
21.

Basic Considerations for the Use of Monoclonal Antibodies in Migraine.

Levin M, Silberstein SD, Gilbert R, Lucas S, Munsie L, Garrelts A, Kennedy K, Everman N, Pearlman E.

Headache. 2018 Nov;58(10):1689-1696. doi: 10.1111/head.13439. Epub 2018 Nov 13.

22.

Health care Resource Utilization and Migraine Disability Along the Migraine Continuum Among Patients Treated for Migraine.

Silberstein SD, Lee L, Gandhi K, Fitzgerald T, Bell J, Cohen JM.

Headache. 2018 Nov;58(10):1579-1592. doi: 10.1111/head.13421. Epub 2018 Oct 30.

PMID:
30375650
23.

From LBR-101 to Fremanezumab for Migraine.

Bigal ME, Rapoport AM, Silberstein SD, Walter S, Hargreaves RJ, Aycardi E.

CNS Drugs. 2018 Nov;32(11):1025-1037. doi: 10.1007/s40263-018-0579-4. Review.

PMID:
30311143
24.

Erenumab in the treatment of migraine.

Jain S, Yuan H, Spare N, Silberstein SD.

Pain Manag. 2018 Nov 1;8(6):415-426. doi: 10.2217/pmt-2018-0037. Epub 2018 Sep 21. Review.

PMID:
30235976
25.

Rationale for electrical parameter determination in external trigeminal nerve stimulation (eTNS) for migraine: A narrative review.

Lauritsen CG, Silberstein SD.

Cephalalgia. 2019 May;39(6):750-760. doi: 10.1177/0333102418796781. Epub 2018 Aug 23.

PMID:
30139273
26.

Ketamine for Refractory Headache: A Retrospective Analysis.

Schwenk ES, Dayan AC, Rangavajjula A, Torjman MC, Hernandez MG, Lauritsen CG, Silberstein SD, Young W, Viscusi ER.

Reg Anesth Pain Med. 2018 Nov;43(8):875-879. doi: 10.1097/AAP.0000000000000827.

PMID:
29923953
27.

Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial.

Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E.

JAMA. 2018 May 15;319(19):1999-2008. doi: 10.1001/jama.2018.4853.

PMID:
29800211
28.

Correction to: OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine.

Frampton JE, Silberstein S.

Drugs. 2018 Apr;78(6):715. doi: 10.1007/s40265-018-0906-6.

29.

The Use and Method of Action of Intravenous Lidocaine and Its Metabolite in Headache Disorders.

Berk T, Silberstein SD.

Headache. 2018 May;58(5):783-789. doi: 10.1111/head.13298. Epub 2018 Mar 14.

PMID:
29536530
30.

OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine.

Frampton JE, Silberstein S.

Drugs. 2018 Apr;78(5):589-600. doi: 10.1007/s40265-018-0894-6. Review. Erratum in: Drugs. 2018 Apr 20;:.

31.

A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study).

Starling AJ, Tepper SJ, Marmura MJ, Shamim EA, Robbins MS, Hindiyeh N, Charles AC, Goadsby PJ, Lipton RB, Silberstein SD, Gelfand AA, Chiacchierini RP, Dodick DW.

Cephalalgia. 2018 May;38(6):1038-1048. doi: 10.1177/0333102418762525. Epub 2018 Mar 4.

32.

Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults.

Tassorelli C, Diener HC, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ; International Headache Society Clinical Trials Standing Committee.

Cephalalgia. 2018 Apr;38(5):815-832. doi: 10.1177/0333102418758283. Epub 2018 Mar 4.

PMID:
29504482
33.

Preventive Therapies for Chronic Migraine.

Silberstein SD, Yeung PP, Aycardi E.

N Engl J Med. 2018 Feb 22;378(8):774. doi: 10.1056/NEJMc1716990. No abstract available.

PMID:
29466162
34.

Current management: migraine headache.

Silberstein SD.

CNS Spectr. 2017 Dec;22(S1):1-13. doi: 10.1017/S1092852917000864.

PMID:
29350125
35.

Percutaneous Closure of Patent Foramen Ovale in Patients With Migraine: The PREMIUM Trial.

Tobis JM, Charles A, Silberstein SD, Sorensen S, Maini B, Horwitz PA, Gurley JC.

J Am Coll Cardiol. 2017 Dec 5;70(22):2766-2774. doi: 10.1016/j.jacc.2017.09.1105.

36.

Fremanezumab for the Preventive Treatment of Chronic Migraine.

Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E.

N Engl J Med. 2017 Nov 30;377(22):2113-2122. doi: 10.1056/NEJMoa1709038.

37.

The emerging role of gammaCore® in the management of cluster headache: expert panel recommendations.

Silberstein SD, Calhoun AH, Treppendahl C, Dodick DW, Rapoport AM, Mamidi A, Vargas P, Ebert TH, Tepper SJ.

Am J Manag Care. 2017 Nov;23(17 Suppl):S326-S333.

38.

CGRP Monoclonal Antibodies for Migraine: Rationale and Progress.

Yuan H, Lauritsen CG, Kaiser EA, Silberstein SD.

BioDrugs. 2017 Dec;31(6):487-501. doi: 10.1007/s40259-017-0250-5. Review.

PMID:
29116598
39.

AVP-825 (Sumatriptan Nasal Powder) Reduces Nausea Compared to Sumatriptan Tablets: Results of the COMPASS Randomized Clinical Trial.

Lipton RB, McGinley JS, Shulman KJ, Silberstein SD, Wirth RJ, Buse DC.

Headache. 2018 Feb;58(2):229-242. doi: 10.1111/head.13199. Epub 2017 Oct 16.

PMID:
29034453
40.

A review of clinical safety data for sumatriptan nasal powder administered by a breath powered exhalation delivery system in the acute treatment of migraine.

Silberstein SD.

Expert Opin Drug Saf. 2018 Jan;17(1):89-97. doi: 10.1080/14740338.2018.1390563. Epub 2017 Oct 20. Review.

PMID:
28994319
41.

Histamine and Migraine.

Yuan H, Silberstein SD.

Headache. 2018 Jan;58(1):184-193. doi: 10.1111/head.13164. Epub 2017 Sep 1. Review.

PMID:
28862769
42.

Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study.

Ashina M, Dodick D, Goadsby PJ, Reuter U, Silberstein S, Zhang F, Gage JR, Cheng S, Mikol DD, Lenz RA.

Neurology. 2017 Sep 19;89(12):1237-1243. doi: 10.1212/WNL.0000000000004391. Epub 2017 Aug 23.

PMID:
28835404
43.

Endocrinology and the brain: corticotropin-releasing hormone signaling.

Inda C, Armando NG, Dos Santos Claro PA, Silberstein S.

Endocr Connect. 2017 Aug;6(6):R99-R120. doi: 10.1530/EC-17-0111. Epub 2017 Jul 14. Review.

44.

AVP-825: a novel intranasal delivery system for low-dose sumatriptan powder in the treatment of acute migraine.

Silberstein S.

Expert Rev Clin Pharmacol. 2017 Aug;10(8):821-832. doi: 10.1080/17512433.2017.1339600. Epub 2017 Jul 3. Review.

PMID:
28605258
45.

cAMP-dependent cell differentiation triggered by activated CRHR1 in hippocampal neuronal cells.

Inda C, Bonfiglio JJ, Dos Santos Claro PA, Senin SA, Armando NG, Deussing JM, Silberstein S.

Sci Rep. 2017 May 16;7(1):1944. doi: 10.1038/s41598-017-02021-7.

46.

Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP-825 Breath Powered® Exhalation Delivery System (Sumatriptan Nasal Powder) vs Oral Sumatriptan.

Silberstein S, Winner PK, McAllister PJ, Tepper SJ, Halker R, Mahmoud RA, Siffert J.

Headache. 2017 Jun;57(6):862-876. doi: 10.1111/head.13105. Epub 2017 May 11.

PMID:
28497569
47.

Neuropeptides.

Silberstein SD.

Headache. 2017 May;57 Suppl 2:35-36. doi: 10.1111/head.13093. No abstract available.

PMID:
28485847
48.

Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.

Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein S, Winner P, Leonardi D, Mikol D, Lenz R.

Lancet Neurol. 2017 Jun;16(6):425-434. doi: 10.1016/S1474-4422(17)30083-2. Epub 2017 Apr 28.

PMID:
28460892
49.

Insights into the Functional Anatomy Behind the PREEMPT Injection Paradigm: Guidance on Achieving Optimal Outcomes.

Blumenfeld AM, Silberstein SD, Dodick DW, Aurora SK, Brin MF, Binder WJ.

Headache. 2017 May;57(5):766-777. doi: 10.1111/head.13074. Epub 2017 Apr 6.

50.

Topiramate in Migraine Prevention: A 2016 Perspective.

Silberstein SD.

Headache. 2017 Jan;57(1):165-178. doi: 10.1111/head.12997. Epub 2016 Nov 30. Review.

PMID:
27902848

Supplemental Content

Loading ...
Support Center